AptarGroup Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de AptarGroup de 7.8% y 5.7% por año respectivamente. Se prevé que el BPA crezca en un 7.5% al año. Se espera que la rentabilidad financiera sea de 12.6% en 3 años.
Información clave
7.8%
Tasa de crecimiento de los beneficios
7.47%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Packaging | 23.3% |
| Tasa de crecimiento de los ingresos | 5.7% |
| Rentabilidad financiera futura | 12.60% |
| Cobertura de analistas | Good |
| Última actualización | 04 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Artículo de análisis • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
Actualización del análisis • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.Actualización del análisis • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).Actualización del análisis • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
Actualización del análisis • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.Actualización del análisis • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Actualización del análisis • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.Actualización del análisis • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).Actualización del análisis • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).Actualización del análisis • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.Artículo de análisis • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Actualización del análisis • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.Actualización del análisis • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).Actualización del análisis • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Seeking Alpha • Nov 02
AptarGroup: Pharma Setback Creates Long-Term Opportunities
Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking AlphaActualización del análisis • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.Artículo de análisis • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...Actualización del análisis • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.Artículo de análisis • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Artículo de análisis • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...Artículo de análisis • Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?
Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Artículo de análisis • May 13
AptarGroup's (NYSE:ATR) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
Nuevo análisis • Aug 25
Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge
Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 4,455 | 437 | N/A | 745 | 3 |
| 12/31/2027 | 4,177 | 402 | 446 | 744 | 8 |
| 12/31/2026 | 3,983 | 349 | 383 | 667 | 8 |
| 3/31/2026 | 3,873 | 387 | 324 | 606 | N/A |
| 12/31/2025 | 3,777 | 393 | 295 | 570 | N/A |
| 9/30/2025 | 3,663 | 419 | 306 | 565 | N/A |
| 6/30/2025 | 3,611 | 392 | 342 | 616 | N/A |
| 3/31/2025 | 3,555 | 370 | 356 | 634 | N/A |
| 12/31/2024 | 3,583 | 375 | 349 | 643 | N/A |
| 9/30/2024 | 3,573 | 336 | 378 | 685 | N/A |
| 6/30/2024 | 3,557 | 320 | 323 | 629 | N/A |
| 3/31/2024 | 3,543 | 313 | 254 | 569 | N/A |
| 12/31/2023 | 3,487 | 284 | 257 | 575 | N/A |
| 9/30/2023 | 3,445 | 281 | 209 | 528 | N/A |
| 6/30/2023 | 3,389 | 251 | 159 | 484 | N/A |
| 3/31/2023 | 3,337 | 232 | 164 | 485 | N/A |
| 12/31/2022 | 3,322 | 239 | 163 | 479 | N/A |
| 9/30/2022 | 3,340 | 238 | 88 | 410 | N/A |
| 6/30/2022 | 3,329 | 231 | 46 | 365 | N/A |
| 3/31/2022 | 3,295 | 223 | 66 | 383 | N/A |
| 12/31/2021 | 3,227 | 244 | 56 | 363 | N/A |
| 9/30/2021 | 3,163 | 240 | 156 | 448 | N/A |
| 6/30/2021 | 3,096 | 256 | 256 | 518 | N/A |
| 3/31/2021 | 2,985 | 243 | 307 | 557 | N/A |
| 12/31/2020 | 2,929 | 214 | 318 | 570 | N/A |
| 9/30/2020 | 2,851 | 209 | 283 | 516 | N/A |
| 6/30/2020 | 2,793 | 202 | 273 | 521 | N/A |
| 3/31/2020 | 2,837 | 234 | 261 | 522 | N/A |
| 12/31/2019 | 2,860 | 242 | N/A | 514 | N/A |
| 9/30/2019 | 2,873 | 234 | N/A | 484 | N/A |
| 6/30/2019 | 2,838 | 217 | N/A | 380 | N/A |
| 3/31/2019 | 2,806 | 198 | N/A | 340 | N/A |
| 12/31/2018 | 2,765 | 195 | N/A | 314 | N/A |
| 9/30/2018 | 2,706 | 204 | N/A | 269 | N/A |
| 6/30/2018 | 2,664 | 218 | N/A | 330 | N/A |
| 3/31/2018 | 2,571 | 228 | N/A | 338 | N/A |
| 12/31/2017 | 2,469 | 220 | N/A | 325 | N/A |
| 9/30/2017 | 2,382 | 220 | N/A | 388 | N/A |
| 6/30/2017 | 2,348 | 220 | N/A | 390 | N/A |
| 3/31/2017 | 2,350 | 214 | N/A | 352 | N/A |
| 12/31/2016 | 2,331 | 206 | N/A | 325 | N/A |
| 9/30/2016 | 2,339 | 199 | N/A | 296 | N/A |
| 6/30/2016 | 2,335 | 200 | N/A | 269 | N/A |
| 3/31/2016 | 2,310 | 198 | N/A | 297 | N/A |
| 12/31/2015 | 2,317 | 199 | N/A | 324 | N/A |
| 9/30/2015 | 2,370 | 198 | N/A | 346 | N/A |
| 6/30/2015 | 2,435 | 193 | N/A | 346 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (7.8% al año) de ATR es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (7.8% al año) de ATR crezcan menos que el mercado US (16.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de ATR crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (5.7% al año) de ATR crezcan más despacio que el mercado de US (11.4% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 5.7% al año) de ATR crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ATR sea baja dentro de 3 años (12.6%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/06 05:15 |
| Precio de las acciones al final del día | 2026/05/06 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AptarGroup, Inc. está cubierta por 16 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |